Evotec Appoints David Brister Chief Business Officer

19 September 2006 - Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today that David Brister has been appointed Chief Business Officer and a member of the Company’s Executive Committee. In this newly created role he will coordinate the business development activities of both Evotec’s Pharmaceuticals and Services Divisions, reinforcing the customer focused approach and strategic account management. David will focus on negotiations of partnerships and licensing agreements as well as on the implementation of Evotec’s M&A strategy. He will report to Joern Aldag, President and Chief Executive Officer.

David Brister, 44, brings 22 years of business experience, including 19 years in venture capital and private equity. He will join Evotec with effect from 16 October 2006 following a successful career in developing venture capital businesses at 3i and MVM. Most recently he was a Director at MVM, a venture capital business focused on seed and early stage healthcare investing, where he was one of the two key executives who established the business. During this time he was instrumental in the successful raising of £110 million for MVM’s second life sciences fund. Prior to MVM, he was an Investment Director at 3i plc and before that held sales and commercial positions with Metal Box plc.
David Brister holds a BSc honours degree in Genetics & Zoology from Sheffield University, UK.

Joern Aldag, President and Chief Executive Officer of Evotec, said: “David is a powerful individual with strengths in strategic thinking and financial analysis, coupled with particularly strong negotiation skills. His transaction experience will be an excellent addition as we continue to ramp up our efforts to build our business through licensing, joint research partnerships and M&A. We welcome him to our team.”

David Brister commented: “Evotec is at a very exciting point in its evolution. In particular, its proprietary CNS pipeline has several extremely promising clinical programmes of which the first will hopefully become ready for partnering during the next 24 months or so. I am very much looking forward to working with the team to continue to enhance Evotec’s delivery of pharmaceutical innovation to its partners and customers.”

About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has two programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, and EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and/or neuropathic pain.
In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
In 2005, Evotec has generated sales of EUR 80 million with 600 employees located in Hamburg, Germany and near Oxford and in Glasgow, UK.

Contact Information

Anne Hennecke

Director, Investor Relations & Corporate Communications

Evotec AG

Contact via E-mail